Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials

In SARS-CoV-2-naïve individuals, a two-dose vaccine regimen is needed to provide antibody levels correlated with protection against disease caused by the cognate virus strain. In contrast, in individuals with prior SARS-CoV-2 acquisition, a single dose of any of the tested vaccines/platforms (mRNA/protein/vector) provides comparably high antibody levels.

Authors

Institutions

Publication Details

Journal
Vaccine
Published
2026-02-22
DOI
https://doi.org/10.1016/j.vaccine.2026.128380
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials

de Bruyn G, Yunda Huang, Matthew B. Laurens, Anne-Marie Rick et al.
Vaccine
SARS-CoV-2 and COVID-19 Research
article

Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials

de Bruyn G, Yunda Huang, Matthew B. Laurens, Anne-Marie Rick, Frances Priddy, Samuel T. Robinson, Karen Kotloff, Jenny Hendriks, Stephen R. Walsh, Holly E. Janes, Lawrence Corey, Richard A. Koup, Hana M. El Sahly, Kathleen M. Neuzil, Kathryn Shoemaker, Beatriz Grinsztejn, James G. Kublin, Dean Follmann, Scott Borgetti, Lindsey R. Baden, Peter B. Gilbert, Magdalena E. Sobieszczyk, Ann R. Falsey, Nadine Rouphael, Paul A. Goepfert, Louis Devlin, Glenda E. Gray, Lisa M. Dunkle
article en

Abstract

In SARS-CoV-2-naïve individuals, a two-dose vaccine regimen is needed to provide antibody levels correlated with protection against disease caused by the cognate virus strain. In contrast, in individuals with prior SARS-CoV-2 acquisition, a single dose of any of the tested vaccines/platforms (mRNA/protein/vector) provides comparably high antibody levels.

VaccineVol. 77
South African Medical Research Council (ZA), University of North Carolina at Chapel Hill (US), University of Maryland, Baltimore (US), Brigham and Women's Hospital (US), National Institutes of Health (US), Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA), Harvard University (US), Baylor College of Medicine (US), Columbia University Irving Medical Center (US), University of Alabama at Birmingham (US), University of Illinois Chicago (US), Fred Hutch Cancer Center (US), Novavax (United States) (US), Moderna Therapeutics (United States) (US), Sanofi (United States) (US), HOPE Clinic (US), National Institute of Allergy and Infectious Diseases (US), University of Pittsburgh Medical Center (US), AstraZeneca (United States) (US), Janssen (Netherlands) (NL), Fundação Oswaldo Cruz (BR), University of Rochester (US)
Openalex Percentile: Top 47%
SARS-CoV-2 and COVID-19 Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.